| Literature DB >> 27322539 |
Donghee Park1, Gillsoo Song2, Yongjun Jo3, Jongho Won2, Taeyoon Son2, Ohrum Cha2, Jinho Kim2, Byungjo Jung2, Hyunjin Park4, Chul-Woo Kim1, Jongbum Seo2.
Abstract
Sonophoresis can increase skin permeability to various drugs in transdermal drug delivery. Cavitation is recognized as the predominant mechanism of sonophoresis. Recently, a new logical approach to enhance the efficiency of transdermal drug delivery was tried. It is to utilize the engineered microbubble and its resonant frequency for increase of cavitation activity. Actively-induced cavitation with low-intensity ultrasound (less than ~1 MPa) causes disordering of the lipid bilayers and the formation of aqueous channels by stable cavitation which indicates a continuous oscillation of bubbles. Furthermore, the mutual interactions of microbubble determined by concentration of added bubble are also thought to be an important factor for activity of stable cavitation, even in different characteristics of drug. In the present study, we addressed the dependence of ultrasound contrast agent concentration using two types of drug on the efficiency of transdermal drug delivery. Two types of experiment were designed to quantitatively evaluate the efficiency of transdermal drug delivery according to ultrasound contrast agent concentration. First, an experiment of optical clearing using a tissue optical clearing agent was designed to assess the efficiency of sonophoresis with ultrasound contrast agents. Second, a Franz diffusion cell with ferulic acid was used to quantitatively determine the amount of drug delivered to the skin sample by sonophoresis with ultrasound contrast agents. The maximum enhancement ratio of sonophoresis with a concentration of 1:1,000 was approximately 3.1 times greater than that in the ultrasound group without ultrasound contrast agent and approximately 7.5 times greater than that in the control group. These results support our hypothesis that sonophoresis becomes more effective in transdermal drug delivery due to the presence of engineered bubbles, and that the efficiency of transdermal drug delivery using sonophoresis with microbubbles depends on the concentration of microbubbles in case stable cavitation is predominant.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27322539 PMCID: PMC4913954 DOI: 10.1371/journal.pone.0157707
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Experiment setup of ultrasound application.
Fig 2Optical properties measurement system.
Fig 3The efficiency of sonophoresis at two ultrasound frequencies for four different concentrations of Definity®.
Fig 4The efficiency of sonophoresis at two ultrasound frequencies for four different concentrations of SonoVue®.
Fig 5The efficiency of sonophoresis at two ultrasound frequencies and three different concentrations of Definity®.
Fig 6The efficiency of sonophoresis at two ultrasound frequencies for three different concentrations of SonoVue®.
Steady state flux values of diffusion and ultrasound with Definity® by Franz diffusion cell (mean ± S.D).
| Definity® | |||
|---|---|---|---|
| Concentration | Diffusion | 1.12MHz | 2.47MHz |
| Flux (μg/ | Flux (μg/ | Flux (μg/ | |
| 7.12±1.78 | 17.33±3.05 | 17.50±2.73 | |
| - | 21.83±3.88 | 21.89±1.07 | |
| - | 51.78±5.21 | 54.31±3.12 | |
| - | 22.91±4.75 | 22.91±4.36 | |
Steady state flux values of diffusion and ultrasound with Sonovue® by Franz diffusion cell (mean ± S.D).
| Sonovue® | |||
|---|---|---|---|
| Concentration | Diffusion | 1.12MHz | 2.47MHz |
| Flux (μg/ | Flux (μg/ | Flux (μg/ | |
| 7.12±1.78 | 17.33±3.05 | 17.50±2.73 | |
| - | 24.22±2.23 | 20.75±2.55 | |
| - | 45.37±5.94 | 37.50±2.62 | |
| - | 14.59±2.14 | 22.51±1.09 | |